Insmed assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Insmed (INSM) with an Overweight rating and $192 price target Following a strong re-rating, Insmed has become a popular long, supported by the brensocatib launch, growing confidence in Treprostinil Palmitil Inhalation Powder, and a credible management team, the analyst tells investors in a research note. The story appears far from over as the company evolves into a diversified, respiratory-focused growth platform, and the near-term brensocatib launch, pipeline depth, and proven execution together create a compelling setup for continued momentum, the firm says.